Piperidylthiambutene, also known as Piperidinohton, belongs to the thiambutene family and is a synthetic opioid analgesic drug. It shares a similar potency to morphine. Unlike fentanyl, its analogues, and previously known synthetic opioids, Piperidylthiambutene exhibits a unique chemical structure.
It’s important to note that in certain countries, including the United States, Australia, and New Zealand if Piperidylthiambutene is sold or acquired with the intent for human consumption, it may be categorized as a controlled substance analogue. Piperidylthiambutene emerged as a designer drug in late 2018, gaining attention in the realm of synthetic substances.

IUPAC name
CAS Number54160-31-5 
PubChem CID3041503
Chemical and physical data
Molar mass303.48 g·mol−1



  • What is Piperidylthiambutene?
  • Piperidylthiambutene, also known as Piperidinohton, is a synthetic opioid analgesic. It is a member of the thiambutene family and exhibits a potency similar to that of morphine.
  • How does Piperidylthiambutene differ from other synthetic opioids?
  • Piperidylthiambutene is structurally distinct from commonly known synthetic opioids like fentanyl and its analogues. This sets it apart in terms of its chemical structure.
  • Is Piperidylthiambutene legal to buy and use?
  • The legal status of Piperidylthiambutene varies by country. In some nations, such as the United States, Australia, and New Zealand, it could be considered a controlled substance analogue if obtained for human consumption. Users should be aware of and adhere to the laws in their specific region.
  • When did Piperidylthiambutene first appear on the market?
  • Piperidylthiambutene started gaining attention as a designer drug in late 2018, marking its introduction to the market of synthetic substances.
  • Is Piperidylthiambutene used for medical purposes?
  • Piperidylthiambutene is not typically used for medical purposes but is instead associated with recreational and designer drug use.
  • What are the potential risks associated with Piperidylthiambutene use?
  • Due to its opioid nature, the use of Piperidylthiambutene can pose risks such as addiction, overdose, and adverse health effects. Users should be cautious and well-informed about its potential dangers.
  • Is Piperidylthiambutene readily available for purchase?
  • Piperidylthiambutene may be available through various sources, including the Internet and illicit markets. However, its sale and possession may be illegal in some regions, so individuals should be aware of local laws and regulations.
  • Is there ongoing research on Piperidylthiambutene?
  • Research on this synthetic opioid may be ongoing, particularly in relation to its effects and risks. However, its status as a designer drug may limit the availability of comprehensive scientific studies.
  • Where can I find more information about Piperidylthiambutene?
  • For the most up-to-date and accurate information, it is advisable to consult with medical professionals, local authorities, or drug enforcement agencies regarding the legal status and risks associated with Piperidylthiambutene. Always prioritize your health and safety.


  1. “Piperidylthiambutene” (PDF). NMS Labs. Retrieved on September 14, 2020, this source is a valuable reference for information on Piperidylthiambutene.
  2. Adamson DW, Green AF (January 1950). In a publication from January 1950, this source introduces a new series of analgesics, shedding light on early developments in this field. Nature. 165 (4186), 122.
  3. Adamson DW, Duffin WM, Green AF (January 1951). Published in January 1951, this source discusses “Dithienylbutylamines as analgesics,” which represents a significant step in the evolution of analgesic compounds. Nature. 167 (4239), 153–4.
  4. Green AF (March 1953). In this March 1953 publication, Green delves into the “Analgesic and other properties of 3: 3-dithienylalkenylamines,” providing insights into the pharmacological properties of certain compounds. British Journal of Pharmacology and Chemotherapy. 8 (1), 2–9.
  5. “Analytical report Piperidylthiambutene” (PDF). European Project Response. This analytical report, dated November 2018, is a crucial resource for understanding Piperidylthiambutene and its implications.
  6. Vandeputte MM, Cannaert A, Stove CP (November 2020). Published in November 2020, this source focuses on the “In vitro functional characterization of a panel of non-fentanyl opioid new psychoactive substances,” contributing to the understanding of these substances. Archives of Toxicology. 94 (11), 3819–3830.
  7. Adamson Donald Wallace, U.S. Patent 2,561,899 (1951 to Burroughs Wellcome Co). This U.S. patent from 1951, awarded to Adamson, is a significant milestone in the development of certain chemical compounds, potentially including Piperidylthiambutene.

Leave a Comment

Your email address will not be published. Required fields are marked *